0000912061-18-000022.txt : 20180502 0000912061-18-000022.hdr.sgml : 20180502 20180502090847 ACCESSION NUMBER: 0000912061-18-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180502 DATE AS OF CHANGE: 20180502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 18797735 BUSINESS ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 BUSINESS PHONE: 310-541-0888 MAIL ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 10-Q 1 nhtc20180502_10q.htm 10-Q Document
false--12-31Q120180000912061YesAccelerated Filer0.0010.001500000005000000012979414129794140.0010.001500000050000000000P3Y16375241603322 0000912061 2018-01-01 2018-03-31 0000912061 2018-03-31 0000912061 2017-12-31 0000912061 2017-01-01 2017-03-31 0000912061 2016-12-31 0000912061 2017-03-31 0000912061 country:TW 2017-01-01 2017-03-31 0000912061 country:CN 2018-01-01 2018-03-31 0000912061 country:SG 2017-01-01 2017-03-31 0000912061 us-gaap:EuropeMember 2018-01-01 2018-03-31 0000912061 us-gaap:AmericasMember 2017-01-01 2017-03-31 0000912061 country:JP 2017-01-01 2017-03-31 0000912061 country:KR 2017-01-01 2017-03-31 0000912061 country:KR 2018-01-01 2018-03-31 0000912061 nhtc:RussiaandKazakhstanDomain 2018-01-01 2018-03-31 0000912061 country:SG 2018-01-01 2018-03-31 0000912061 us-gaap:EuropeMember 2017-01-01 2017-03-31 0000912061 country:HK 2018-01-01 2018-03-31 0000912061 country:HK 2017-01-01 2017-03-31 0000912061 country:MY 2017-01-01 2017-03-31 0000912061 country:TW 2018-01-01 2018-03-31 0000912061 us-gaap:AmericasMember 2018-01-01 2018-03-31 0000912061 country:JP 2018-01-01 2018-03-31 0000912061 country:CN 2017-01-01 2017-03-31 0000912061 nhtc:RussiaandKazakhstanDomain 2017-01-01 2017-03-31 0000912061 country:MY 2018-01-01 2018-03-31 0000912061 us-gaap:CashEquivalentsMember 2018-03-31 0000912061 us-gaap:CashMember 2017-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2018-03-31 0000912061 nhtc:AutoShipAdvancesMember 2018-03-31 0000912061 nhtc:UnshippedProductMember 2018-03-31 0000912061 nhtc:UnshippedProductMember 2017-12-31 0000912061 nhtc:AutoShipAdvancesMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember 2017-12-31 0000912061 us-gaap:CashMember 2018-03-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2017-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2018-03-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2018-03-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2017-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2018-03-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2017-12-31 0000912061 2016-01-12 0000912061 us-gaap:RestrictedStockMember 2018-02-01 2018-02-01 0000912061 2018-02-06 2018-02-06 0000912061 2018-02-01 2018-02-01 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 2015-07-28 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-03-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-03-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-01-01 2018-03-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-03-31 0000912061 nhtc:ShareholderderivativeclaimMember 2018-01-01 2018-03-31 0000912061 nhtc:SecuritiesClassActionMember 2018-01-01 2018-03-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-03-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2018-01-01 2018-03-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2013-02-01 2013-02-28 0000912061 us-gaap:SubsequentEventMember 2018-04-17 2018-04-17 xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares utreg:Rate


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
(Mark One)
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2018
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ______ to _______
 
Commission File Number: 001-36849
NATURAL HEALTH TRENDS CORP.
(Exact name of registrant as specified in its charter)
Delaware
59-2705336
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
609 Deep Valley Drive
Suite 395
Rolling Hills Estates, California 90274
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (310) 541-0888
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files). Yes þ No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): 
Large accelerated filer o
Accelerated filer þ
Non-accelerated filer   o
Smaller reporting company o
(Do not check if a smaller reporting company)
Emerging growth company o
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No þ
 
At April 27, 2018, the number of shares outstanding of the registrant’s common stock was 11,376,092 shares.




NATURAL HEALTH TRENDS CORP.
Quarterly Report on Form 10-Q
March 31, 2018
 
INDEX 
 




FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q, in particular “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.
 
Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.
 
For a summary of certain risks related to our business, see “Part I, Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K, as modified by the disclosure set forth in “Part II, Item 1A. Risk Factors” in this report, which includes the following:
We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants;
Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business;
Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company;
Our failure to maintain and expand our member relationships could adversely affect our business;
We are currently being sued in two derivative lawsuits alleging, among other things, that we made materially false and misleading statements regarding the legality of our business operations in China;
We are currently involved in, and may in the future face, litigation claims and governmental proceedings and inquiries that could harm our business;
Although our members are independent contractors, improper member actions that violate laws or regulations could harm our business;
Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business;
The high level of competition in our industry could adversely affect our business;
Challenges by third parties to the legality of our business operations could harm our business;
An increase in the amount of compensation paid to members would reduce profitability;
Currency exchange rate fluctuations could lower our revenue and net income;
Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income;
Transfer pricing regulations affect our business and results of operations;
Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets;
Failure of new products to gain member and market acceptance could harm our business;
New regulations governing the marketing and sale of nutritional supplements could harm our business;
Regulations governing the production and marketing of our personal care products could harm our business;
If we are found not to be in compliance with good manufacturing practices our operations could be harmed;




Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business;
Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;
We are subject to risks relating to product concentration and lack of revenue diversification;
We rely on a limited number of independent third parties to manufacture and supply our products;
Growth may be impeded by the political and economic risks of entering and operating foreign markets;
We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results;
We may be unable to protect or use our intellectual property rights;
We do not have a comprehensive product liability insurance program and product liability claims could hurt our business;
Our internal controls and accounting methods may require modification;
We identified a material weakness in our internal control over financial reporting. If we do not adequately address this material weakness or if other material weaknesses or significant deficiencies in our internal control over financial reporting are discovered, our financial statements could contain material misstatements and our business, operations and stock price may be adversely affected;
We rely on and are subject to risks associated with our reliance upon information technology systems;
System disruptions or failures, cybersecurity risks, and compromises of data could harm our business;
Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business;
Terrorist attacks, acts of war, epidemics or natural disasters may seriously harm our business;
We may experience substantial negative cash flows, which may have a significant adverse effect on our business and could threaten our solvency;
If we experience negative cash flows, we may need to seek additional debt or equity financing, which may not be available on acceptable terms or at all. If available, it could have a highly dilutive effect on the holdings of existing stockholders;
Disappointing quarterly revenue or operating results could cause the price of our common stock to fall;
Our common stock is particularly subject to volatility because of the industry in which we operate;
Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive; and
Future sales by us or our existing stockholders could depress the market price of our common stock.

Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our financial statements and the related notes.




PART I - FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
  
NATURAL HEALTH TRENDS CORP.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
 
 
March 31, 2018
 
December 31, 2017
 
(Unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
145,095

 
$
135,311

Inventories
7,944

 
8,398

Other current assets
6,021

 
7,534

Total current assets
159,060

 
151,243

Property and equipment, net
1,040

 
1,149

Goodwill
1,764

 
1,764

Restricted cash
3,279

 
3,167

Deferred tax asset
1,435

 
1,435

Other assets
809

 
796

Total assets
$
167,387

 
$
159,554

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
2,669

 
$
1,751

Income taxes payable
42

 
309

Accrued commissions
10,027

 
11,170

Other accrued expenses
8,549

 
7,605

Deferred revenue
4,112

 
4,455

Amounts held in eWallets
14,623

 
15,152

Other current liabilities
1,756

 
1,479

Total current liabilities
41,778

 
41,921

Income taxes payable
19,052

 
19,052

Deferred tax liability
55

 
56

Long-term incentive
7,596

 
7,904

Total liabilities
68,481

 
68,933

Commitments and contingencies (Note 9)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at March 31, 2018 and December 31, 2017
13

 
13

Additional paid-in capital
86,415

 
86,683

Retained earnings
52,253

 
44,908

Accumulated other comprehensive loss
(27
)
 
(413
)
Treasury stock, at cost; 1,603,322 and 1,637,524 shares at March 31, 2018 and December 31, 2017, respectively
(39,748
)
 
(40,570
)
Total stockholders’ equity
98,906

 
90,621

Total liabilities and stockholders’ equity
$
167,387

 
$
159,554

 
See accompanying notes to consolidated financial statements.

1



NATURAL HEALTH TRENDS CORP. 
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
 
Three Months Ended March 31,
 
2018
 
2017
Net sales
$
52,367

 
$
59,874

Cost of sales
10,221

 
11,245

Gross profit
42,146

 
48,629

Operating expenses:
 
 
 
Commissions expense
22,980

 
25,965

Selling, general and administrative expenses
9,122

 
9,672

Total operating expenses
32,102

 
35,637

Income from operations
10,044

 
12,992

Other income, net
163

 
156

Income before income taxes
10,207

 
13,148

Income tax provision
1,383

 
2,723

Net income
$
8,824

 
$
10,425

Net income per common share:
 
 
 
Basic
$
0.78

 
$
0.93

Diluted
$
0.78

 
$
0.93

Weighted-average number of common shares outstanding:
 
 
 
Basic
11,286

 
11,229

Diluted
11,288

 
11,251

Cash dividends declared per common share
$
0.13

 
$
0.44

 
See accompanying notes to consolidated financial statements.
 

2



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(In thousands)
 
 
Three Months Ended March 31,
 
2018
 
2017
Net income
$
8,824

 
$
10,425

Other comprehensive income (loss), net of tax:
 
 
 
Foreign currency translation adjustment
397

 
76

Release of cumulative translation adjustment

 
(258
)
Net change in foreign currency translation adjustment
397

 
(182
)
Unrealized losses on available-for-sale securities
(11
)
 
(7
)
Comprehensive income
$
9,210

 
$
10,236

 
See accompanying notes to consolidated financial statements.
 

3



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
 
Three Months Ended March 31,
 
2018
 
2017
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income
$
8,824

 
$
10,425

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
131

 
136

Stock-based compensation

 
9

Cumulative translation adjustment realized in net income

 
(258
)
Changes in assets and liabilities:
 
 
 
Inventories
473

 
2,091

Other current assets
1,548

 
1,419

Other assets
(5
)
 
(62
)
Accounts payable
920

 
(61
)
Income taxes payable
(275
)
 
1,798

Accrued commissions
(1,119
)
 
(428
)
Other accrued expenses
1,483

 
(1,555
)
Deferred revenue
(333
)
 
(647
)
Amounts held in eWallets
(466
)
 
1,138

Other current liabilities
272

 
314

Long-term incentive
(308
)
 
(508
)
Net cash provided by operating activities
11,145

 
13,811

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(17
)
 
(72
)
Net cash used in investing activities
(17
)
 
(72
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Dividends paid
(1,479
)
 
(4,981
)
Net cash used in financing activities
(1,479
)
 
(4,981
)
Effect of exchange rates on cash, cash equivalents and restricted cash
247

 
22

Net increase in cash, cash equivalents and restricted cash
9,896

 
8,780

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period
138,478

 
128,884

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period
$
148,374

 
$
137,664

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:
 
 
 
Issuance of treasury stock for employee awards, net
$
554

 
$
1,393

 
See accompanying notes to consolidated financial statements.

4



NATURAL HEALTH TRENDS CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

Nature of Operations 
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 27, 2018.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

Reclassification

In accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, the Company has included amounts classified as restricted cash or restricted cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows.

2. ACCOUNTING PRONOUNCEMENTS
 
In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.


5



In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities had the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that began after December 15, 2017, including interim reporting periods. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 3 for additional information.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

3. REVENUE

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts With Customers, which was adopted on January 1, 2018 using the modified retrospective method. All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were 2% of sales for the three months ended March 31, 2018 and 2017.  No material changes in estimates have been recognized during the periods presented. See Note 5 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended March 31, 2018 is primarily due to $3.2 million of revenue recognized which was included in deferred revenue as of December 31, 2017, offset by cash payments received or due in advance of satisfying the Company’s performance obligations. See Note 5 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider.


6



The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended March 31,
 
2018
 
2017
Americas1
$
1,536

 
2.9
%
 
$
1,460

 
2.4
%
Hong Kong2
47,619

 
91.0

 
54,567

 
91.1

China
1,259

 
2.4

 
1,754

 
2.9

Taiwan
1,061

 
2.0

 
1,158

 
2.0

South Korea
119

 
0.2

 
122

 
0.2

Japan
65

 
0.1

 
27

 

Singapore
31

 
0.1

 
45

 
0.1

Malaysia
43

 
0.1

 

 

Russia and Kazakhstan
203

 
0.4

 
217

 
0.4

Europe
431

 
0.8

 
524

 
0.9

Total
$
52,367

 
100.0
%
 
$
59,874

 
100.0
%

1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K.

The Company’s net sales by product and service are as follows (in thousands):
 
Three Months Ended March 31,
 
2018
 
2017
Product sales
$
49,365

 
$
56,577

Freight and other
3,752

 
4,636

Less: sales returns
(750
)
 
(1,339
)
Total net sales
$
52,367

 
$
59,874



Concentration

No single market other than Hong Kong had net sales greater than 10% of total net sales and no single customer accounted for 10% or more of net sales for the three months ended March 31, 2018 and 2017. The Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.


7



4. NET INCOME PER COMMON SHARE

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended March 31,
 
2018
 
2017
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
8,824

 
11,286

 
$
0.78

 
$
10,425

 
11,229

 
$
0.93

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
2

 
 

 

 
22

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
8,824

 
11,288

 
$
0.78

 
$
10,425

 
11,251

 
$
0.93


Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling 28,747 shares were not included for the three months ended March 31, 2018.


8



5. BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
March 31, 2018
 
December 31, 2017
Cash, cash equivalents and restricted cash:
 
 
 
Cash
$
70,249

 
$
61,703

Cash equivalents
74,846

 
73,608

 
145,095

 
135,311

Restricted cash
3,279

 
3,167

 
$
148,374

 
$
138,478

Inventories:
 
 
 
Finished goods
$
7,524

 
$
7,779

Raw materials
572

 
799

Inventory reserve for obsolescence
(152
)
 
(180
)
 
$
7,944

 
$
8,398

Other accrued expenses:
 
 
 
Sales returns
$
689

 
$
614

Employee-related expense
5,316

 
5,568

Warehousing, inventory-related and other
2,544

 
1,423

 
$
8,549

 
$
7,605

Deferred revenue:
 
 
 
Unshipped product
$
2,017

 
$
2,411

Auto ship advances
1,740

 
1,665

Other
355

 
379

 
$
4,112

 
$
4,455



6. FAIR VALUE MEASUREMENTS

As of March 31, 2018, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at March 31, 2018 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.


9



Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
March 31, 2018
 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Municipal bonds and notes
$
5,155

 
$
(1
)
 
$
5,154

 
$
13,320

 
$
(1
)
 
$
13,319

Corporate debt securities
54,075

 
(36
)
 
54,039

 
49,432

 
(24
)
 
49,408

Financial institution instruments
15,653

 

 
15,653

 
10,881

 

 
10,881

Total available-for-sale investments
$
74,883

 
$
(37
)
 
$
74,846

 
$
73,633

 
$
(25
)
 
$
73,608


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.

7. STOCKHOLDERS’ EQUITY
 
Dividends

On February 6, 2018, the Board of Directors declared a cash dividend of $0.13 on each share of common stock outstanding. Such dividends were paid on March 9, 2018 to stockholders of record on February 27, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of March 31, 2018, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

No stock-based compensation was recognized for the three months ended March 31, 2018. Stock-based compensation expense totaled $8,700 for the three months ended March 31, 2017.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At March 31, 2018, 2,359,671 shares remained available for issuance under the 2016 Plan.

On February 1, 2018, the Company granted 34,202 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2017 performance incentives totaling $554,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.


10



The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2017
58,032

 
$
28.59

Granted
34,202

 
16.19

Vested
(11,687
)
 
26.31

Nonvested at March 31, 2018
80,547

 
23.65



Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first three months of 2018 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2017
$
(386
)
 
$
(27
)
 
$
(413
)
Other comprehensive income (loss)
397

 
(11
)
 
386

Balance, March 31, 2018
$
11

 
$
(38
)
 
$
(27
)


8. INCOME TAXES

The effective income tax rate for the three months ended March 31, 2018 was significantly impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which affected the Company’s year ended December 31, 2017, including, but not limited to, reducing the maximum U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018, and requiring a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings, which is payable over eight years beginning with 8% of the liability due with the filing of the year ended December 31, 2017 federal tax return that will be due in 2018.

On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in the corporate income tax rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in the Company’s interpretations and assumptions, additional guidance that may be issued by the Internal Revenue Service, and actions it may take. The Company is continuing to gather additional information to determine the final impact. Any adjustments recorded to the provisional amounts through the fourth quarter of 2018 will be included as an adjustment to income tax expense.


11



Effective January 1, 2018, the Company is subject to the new Global Intangible Low-Taxed Income (“GILTI”) tax rules. GILTI is the excess income of foreign subsidiaries over a 10% routine return on tangible assets. After a 50% deduction, GILTI is subject to the 21% corporate tax rate. Due to the complexity of the GILTI tax rules, the Company continues to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, the Company is allowed to make an accounting policy choice of either treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or factoring such amounts into the Company’s measurement of its deferred taxes (the “deferred method”). Although the Company has not elected an accounting policy, it has recorded a provisional amount of the GILTI tax as a current period expense for 2018. The impact of GILTI on the effective tax rate for the three months ended March 31, 2018 was approximately 10%, or $1.0 million, net of foreign tax credits attributed to GILTI. The Company will determine the appropriate accounting policy for its structure and record any necessary adjustments within the measurement period.

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. Due to the adoption of a territorial tax regime upon the enactment of the Tax Act, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on the Company’s effective tax rate. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of March 31, 2018, the Company has accrued tax liabilities for earnings that it plans to repatriate out of accumulated earnings in future periods for state tax purposes only. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of March 31, 2018.

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2016 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2012. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries except that the Taiwan Taxation Administration is currently examining the Taiwan subsidiary’s 2016 tax return. No material adjustment is anticipated.

9. COMMITMENTS AND CONTINGENCIES

Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. On April 2, 2018, the court approved a class-wide settlement of the action in the amount of $1.75 million, which will be fully funded by the Company’s insurers. 

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China, and it has made materially false and misleading statements regarding the legality of its business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies.


12



On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the Zhou matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The Zhou court entered an order continuing the stay on November 17, 2017.  On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the Kleinfeldt action. On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement.  On April 4, 2018, the court entered an order preliminarily approving the proposed settlement and setting a final hearing for July 16, 2018. If final approval is granted, the proposed settlement will require certain corporate governance reforms and permit an award of up to $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement does not become final. If the proposed settlement is not finalized, the Derivative Complaints could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

Other Claims

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.

10. RELATED PARTY TRANSACTIONS

In February 2013, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were $83,000 and $91,000 for the three months ended March 31, 2018 and 2017, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.

11. SUBSEQUENT EVENT
 
On April 17, 2018, the Board of Directors declared a quarterly cash dividend of $0.14 and a special cash dividend of $1.76 on each share of common stock outstanding. Such dividends are payable on May 25, 2018 to stockholders of record on May 15, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.


13



Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Business Overview
 
We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. We also operate through an engagement of a third-party service provider in Russia and Kazakhstan.
 
Our member network operates in a seamless manner from market to market, except for our China market where we sell to consumers through an e-commerce platform, and our Russia and Kazakhstan market where our engagement of a third-party service provider results in a different economic structure than in our other markets. Otherwise, we believe that all of our other operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. There is no separate segment manager who is held accountable by our chief operating decision-makers, or anyone else, for operations, operating results and planning for the China market or the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, we consider ourselves to be in a single reporting segment and operating unit structure. 
 
As of March 31, 2018, we were conducting business through 95,040 active members, compared to 95,670 three months ago and 113,710 a year ago. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia and Europe. We also invested some resources in Mexico and Peru last year.
 
We generate approximately 97% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 91% of net sales in the latest fiscal quarter. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. For further information regarding some of the risks associated with the conduct of our business in China, see generally in “Part I, Item 1A, Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...” and “Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.
 
China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities requires a direct selling license in China, which we do not currently hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.


14



Income Statement Presentation
 
We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recognized when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. We bill members for shipping charges and recognize the freight revenue in net sales. We have elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrue for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Event and training revenue is deferred and recognized as the event or training occurs.
 
Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.
 
Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (in some markets, sales are for personal consumption only and income may not be earned through retail profits).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for the first three months of 2018 and 2017, represented 44% and 43%, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.
 
Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly. 


15



The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar, see “Item 3. Quantitative and Qualitative Disclosures About Market Risk” and more specifically under the caption “Foreign Currency Exchange Risk” for further information. 

Results of Operations 
 
The following table sets forth our operating results as a percentage of net sales for the periods indicated.
 
Three Months Ended March 31,
 
2018
 
2017
Net sales
100.0
%
 
100.0
%
Cost of sales
19.5

 
18.8

Gross profit
80.5

 
81.2

Operating expenses:
 
 
 
Commissions expense
43.9

 
43.4

Selling, general and administrative expenses
17.4

 
16.1

Total operating expenses
61.3

 
59.5

Income from operations
19.2

 
21.7

Other income, net
0.3

 
0.3

Income before income taxes
19.5

 
22.0

Income tax provision
2.6

 
4.5

Net income
16.9
%
 
17.5
%

Net Sales
 
The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended March 31,
 
2018
 
2017
Americas1
$
1,536

 
2.9
%
 
$
1,460

 
2.4
%
Hong Kong2
47,619

 
91.0

 
54,567

 
91.1

China
1,259

 
2.4

 
1,754

 
2.9

Taiwan
1,061

 
2.0

 
1,158

 
2.0

South Korea
119

 
0.2

 
122

 
0.2

Japan
65

 
0.1

 
27

 

Singapore
31

 
0.1

 
45

 
0.1

Malaysia
43

 
0.1

 

 

Russia and Kazakhstan
203

 
0.4

 
217

 
0.4

Europe
431

 
0.8

 
524

 
0.9

Total
$
52,367

 
100.0
%
 
$
59,874

 
100.0
%
1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K.
 

16



Net sales were $52.4 million for the three months ended March 31, 2018 compared with $59.9 million for the comparable period a year ago, a decrease of $7.5 million, or 13%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased $6.9 million, or 13%, over the comparable period a year ago. The sales decrease was primarily attributable to the slowdown we have been experiencing in our Asian markets since the third quarter of 2016, which has impaired our members’ ability to conduct business and impacted the operations of our logistics partners. In addition, Hong Kong experienced a decrease of 21,600 active members, or 21%, from March 31, 2017 to March 31, 2018, which contributed to the decrease in product sales volume.

Outside of our Hong Kong business, net sales decreased $559,000, or 11%, over the comparable three month period a year ago, driven largely by a 28% decrease in our China e-commerce business. The $495,000 net sales decrease in our China e-commerce business was primarily the result of decreased sales of our Home product line, partially offset by increased sales of our Wellness product line.

As of March 31, 2018, deferred revenue was $4.1 million, which primarily consisted of $2.0 million pertaining to unshipped product orders and $1.7 million pertaining to auto ship advances.
 
Gross Profit
 
Gross profit was 80.5% of net sales for the three months ended March 31, 2018 compared with 81.2% of net sales for the three months ended March 31, 2017. The gross profit margin percentage decrease was primarily due to lower event revenue.

Commissions
 
Commissions were 43.9% of net sales for the three months ended March 31, 2018, compared with 43.4% of net sales for the three months ended March 31, 2017. The slight increase as a percentage of net sales for the three month period ended March 31, 2018 primarily resulted from higher estimated costs for on-going cash and other incentive programs.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $9.1 million for the three months ended March 31, 2018 compared with $9.7 million in the same period a year ago. Selling, general and administrative expenses decreased by 6% during the three month period ended March 31, 2018 mainly due to decreases in professional fees and event costs, as well as a decrease in credit card fees and assessments due to lower net sales, partially offset by an increase in employee-related costs as compared to the same period in the prior year.

Income Taxes
 
An income tax provision of $1.4 million and $2.7 million was recognized during the three month periods ended March 31, 2018 and 2017, respectively. The effective tax rate for the three month period ended March 31, 2018 is less than the comparable period a year ago due to the enactment of the Tax Cuts and Jobs Act (the “Tax Act”) on December 22, 2017 by the U.S. government, which is effective for taxable years beginning on or after January 1, 2018. The Tax Act reduced the maximum U.S. federal corporate income tax rate from 35% to 21%. The primary impact of the Tax Act on the three months ended March 31, 2018 was the inclusion of the tax effects of Global Intangible Low-Taxed Income (“GILTI”). GILTI is the excess income of foreign subsidiaries over a 10% routine return on tangible assets. After a 50% deduction, GILTI is subject to the 21% corporate tax rate. The impact of GILTI on the effective tax rate for the three months ended March 31, 2018 was approximately 10%, or $1.0 million, net of foreign tax credits attributed to GILTI.

Liquidity and Capital Resources
 
At March 31, 2018, our cash and cash equivalents totaled $145.1 million. Total cash and cash equivalents increased by $9.8 million from December 31, 2017 to March 31, 2018. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2018, we had $74.8 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $144.1 million held in bank accounts overseas, which included $9.0 million held in banks located within China subject to foreign currency controls.

As of March 31, 2018, the ratio of current assets to current liabilities was 3.81 to 1.00 and we had $117.3 million of working capital. Working capital as of March 31, 2018 increased $8.0 million compared to our working capital as of December 31, 2017, due primarily to an increase in cash from operations during the three months ended March 31, 2018.
 

17



Cash provided by operations was $11.1 million for the first three months of 2018 compared with $13.8 million in the comparable period of 2017. The decrease in operating cash flows resulted primarily from the decrease in product orders and the impact of our members’ utilization of our eWallet functionality.
 
Cash flows used in investing activities totaled $17,000 during the first three months of 2018. Cash flows used in investing activities totaled $72,000 during the first three months of 2017 and consisted primarily of capitalizable software development costs and buildout costs for our expansion into Peru and Vietnam.
 
Cash flows used in financing activities during the first three months of 2018 and 2017 consisted solely of dividend payments totaling $1.5 million and $5.0 million, respectively.

On April 17, 2018, the Board of Directors declared a quarterly cash dividend of $0.14 and a special cash dividend of $1.76 on each share of common stock outstanding. Such dividends are payable on May 25, 2018 to stockholders of record on May 15, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.
 
We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently we do not believe that will be necessary.

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application. We also invested some resources in Mexico and Peru last year.
 
Critical Accounting Policies and Estimates 
 
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 27, 2018. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to member commissions and income taxes.
 
Revenue Recognition.  Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue. Such amounts totaled $2.0 million and $2.4 million at March 31, 2018 and December 31, 2017, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.


18



Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $1.7 million at March 31, 2018 and December 31, 2017.
 
Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.
 
Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $10.0 million and $11.2 million at March 31, 2018 and December 31, 2017, respectively.
 
Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of March 31, 2018, we no longer have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. The Tax Act, enacted on December 22, 2017 by the U.S. government, requires a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of March 31, 2018, we have accrued tax liabilities for earnings that we plan to repatriate out of accumulated earnings in future periods for state tax purposes only. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of March 31, 2018.

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. Our effective tax rate projected for the year ending December 31, 2018 is 13.6%, which differs from the year ended December 31, 2017 primarily as a result of the Tax Act.


19



Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
We have operations both internationally and within the United States, and we are exposed to market risks in the ordinary course of our business. These risks include primarily interest rate, foreign exchange and inflation risks.

Interest Rate Fluctuation Risk

Our cash and cash equivalents consist of cash, available-for-sale securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The primary objective of our investment in available-for-sale securities is to preserve principal while maximizing income without significantly increasing risk. Because our cash and cash equivalents have a relatively short maturity, our portfolio’s fair value is relatively insensitive to interest rate changes. In future periods, we will continue to evaluate our investment policy relative to our overall objectives.

Foreign Currency Exchange Risk

We have foreign currency risks related to our revenue and expenses denominated in currencies other than the U.S. dollar. Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar. Our foreign currency exchange rate exposure to South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Vietnamese dong, Canadian dollar, Mexican peso, Peruvian sol and European euro represented approximately 7% of our revenue during each of the three month periods ended March 31, 2018 and 2017. We have experienced and will continue to experience fluctuations in our net income as a result of transaction gains and losses related to translating certain balances denominated in currencies other than the U.S. dollar.

Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, Canada, Central America, South America and Europe. Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar. We also experience indirect exchange rate exposure to the Chinese yuan, which affects our Chinese members’ purchasing power. Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition. Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.

Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we might not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.

Item 4. CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures
 
Management, with the participation of the Company’s principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of March 31, 2018. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including the Company’s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that, due to a material weakness in internal control over financial reporting described in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2017, our disclosure controls and procedures were not effective as of March 31, 2018.
 
Changes in Internal Control over Financial Reporting
 
Other than with respect to the remediation efforts discussed below, there were no changes in internal control over financial reporting that occurred during the fiscal quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.


20



Remediation Efforts to Address Material Weakness

Management, with oversight from the Audit Committee, has implemented a plan intended to remediate the material weakness related to our proprietary web-based system and strengthen our internal control environment. The remediation plan includes the following:

Enhancement of controls to ensure that the system change management log is adequately backed up, secured and sufficiently maintained; and

Initiation of periodic review and testing of user access rights and permissions.

During the first quarter of 2018, we began the process of revising our controls related to the backup of our proprietary web-based system change management logs and believe those controls are now providing the necessary audit trail. In addition, management has completed its initial review of user access rights and permissions and will continue to perform periodic reviews of user access rights and permissions; however, the required programming changes necessary to improve user access rights and permissions is on-going. We also continue to review and develop additional controls and procedures to improve our control environment, including compensating review controls for our proprietary web-based system. We expect that the remediation of this material weakness will be fully complete during 2018.


21



PART II — OTHER INFORMATION
 
Item 1. LEGAL PROCEEDINGS

Securities Class Action

In January 2016, two putative securities class action complaints were filed against us and our top executives in the United States District Court for the Central District of California. On March 29, 2016, the court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. On April 2, 2018, the court approved a class-wide settlement of the action in the amount of $1.75 million, which will be fully funded by our insurers.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of our officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed us and our assets. The Derivative Complaints allege, among other things, that we have been running an allegedly illegal multilevel marketing business in China, that we have made materially false and misleading statements regarding the legality of our business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies.

On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the Zhou matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The Zhou court entered an order continuing the stay on November 17, 2017. On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the Kleinfeldt action.  On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement. On April 4, 2018, the court entered an order preliminarily approving the proposed settlement and setting a final hearing for July 16, 2018. If final approval is granted, the proposed settlement will require certain corporate governance reforms and permit an award of up to $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by our insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement does not become final. If the proposed settlement is not finalized, the Derivative Complaints could result in monetary or other penalties that may materially affect our operating results and financial condition.

Item 1A. RISK FACTORS
 
Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2017, except that the following risk factor is modified to reflect the class-wide settlement of the securities class action, referenced in Part II, Item 1 of this report:

22




We are currently being sued in two derivative lawsuits alleging, among other things, that we made materially false and misleading statements regarding the legality of our business operations in China.

Our executive officers and directors are named as defendants in two derivative complaints, purporting to assert claims for breach of fiduciary duties, unjust enrichment, and insider selling, among others, based on allegations that we have been making materially false and misleading statements regarding the legality of our business operations in China, among other things. These complaints seek an indeterminate amount of damages on behalf of the Company, as well as equitable remedies. Although we have entered into a Stipulation of Settlement that has been preliminarily approved by the United States District Court for the Central District of California, there is no guarantee that the proposed settlement of these actions will receive final approval or ultimately become effective. Further, notwithstanding potentially applicable insurance coverage, these complaints, or others filed alleging similar facts, could result in monetary or other penalties that may adversely affect our operating results and financial condition. Moreover, the negative publicity stemming from these complaints and the allegations they make could harm our business and operations. Accordingly, any adverse determination against us in these suits, or even the allegations contained in the suits regardless of whether they are ultimately found to be without merit, could harm our business, operations and financial condition.
 
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES
 
None.
 
Item 4. MINE SAFETY DISCLOSURES
 
Not applicable.
 
Item 5. OTHER INFORMATION
 
None.
 
Item 6. EXHIBITS
 
Exhibit
Number
 
 
Exhibit Description
 
 
 
31.1
 
31.2
 
32.1
 
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

23



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
NATURAL HEALTH TRENDS CORP.
 
 
 
 
Date: May 2, 2018
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 

24



EXHIBIT INDEX
 
Exhibit
Number
 
Exhibit Description
 
 
 
31.1
 
31.2
 
32.1
 
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

25
EX-31.1 2 ex31-1.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
 
CERTIFICATION
 
I, Chris T. Sharng, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 2, 2018
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 


EX-31.2 3 ex31-2.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
 
CERTIFICATION
 
I, Timothy S. Davidson, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 2, 2018
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 


EX-32.1 4 ex32-1.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
 

CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Natural Health Trends Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: May 2, 2018
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 
 
 
 
 
 
 
Date: May 2, 2018
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 
 
The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 5 nhtc-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2207201 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS (Notes) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes) link:presentationLink link:calculationLink link:definitionLink 2212201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 2312302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - INCOME TAXES INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - INCOME TAXES NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2210201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies) link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - REVENUE Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - REVENUE Revenue (Notes) link:presentationLink link:calculationLink link:definitionLink 2208201 - Disclosure - REVENUE Revenue Recognition (Policies) link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - REVENUE Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 2313302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nhtc-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 nhtc-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 nhtc-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Accumulated Other Comprehensive Loss [Abstract] Accumulated Other Comprehensive Loss [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Balance, December 31, 2017 Accumulated Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Balance, March 31, 2018 Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Revenue Recognition [Abstract] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock, Dividends, Per Share, Declared Common Stock, Dividends, Per Share, Declared CommonStockSpecialDividendsPerShareDeclared CommonStockSpecialDividendsPerShareDeclared Special dividends declared during the period for each share of common stock outstanding. Organization, Consolidation and Presentation of Financial Statements [Abstract] Principles of Consolidation Consolidation, Policy [Policy Text Block] NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Stock-based compensation Share-based Compensation Cumulative Translation Adjustment Realized In Net Income Cumulative Translation Adjustment Realized In Net Income Represents cumulative translation adjustment realized in net income. Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventories Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued commissions Increase (Decrease) in Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Amounts held in eWallets Increase (Decrease) in Customer Advances and Deposits Other current liabilities Increase (Decrease) in Other Current Liabilities Long-term incentive Increase (Decrease) in Deferred Compensation Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Dividends paid Payments of Dividends Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Effect of exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase in cash, cash equivalents and restricted cash Cash and Cash Equivalents, Period Increase (Decrease) Cash Cash CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period Cash and Cash Equivalents, at Carrying Value SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: Noncash Investing and Financing Items [Abstract] Issuance of treasury stock for employee awards, net Stock Issued Earnings Per Share [Abstract] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Document And Entity Information Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag SUBSEQUENT EVENT Subsequent Events [Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Income Statement [Abstract] Net sales Sales Revenue, Goods, Net Cost of sales Cost of Goods Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Commissions expense Sales Commissions and Fees Selling, general and administrative expenses Selling, General and Administrative Expense Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income, net Other Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income per common share: Basic (in dollars per share) Earnings Per Share, Basic Earnings Per Share, Diluted Earnings Per Share, Diluted Weighted-average number of common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Cash dividends declared per share: Dividends [Abstract] Common (in dollars per share) Accounting Policies [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Treasury stock, shares Treasury Stock, Shares Earnings Per Share, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Supplemental Balance Sheet Disclosures [Text Block] Supplemental Balance Sheet Disclosures [Text Block] Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Net income Other comprehensive income (loss), net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized losses on available-for-sale securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2016 Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Common Stock Common Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based compensation expense Allocated Share-based Compensation Expense Shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Stock repurchase program, amount authorized Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Common Stock, Dividends, Per Share, Cash Paid Common Stock, Dividends, Per Share, Cash Paid Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Nonvested, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested, beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Nonvested, ending balance (in dollars per share) Stock Issued During Period, Value, Restricted Stock Award, Gross Stock Issued During Period, Value, Restricted Stock Award, Gross Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Products and Services [Table Text Block] Revenue from External Customers by Products and Services [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Summary of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Municipal Bonds and Notes [Member] Municipal Bonds and Notes [Member] Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments. Corporate Debt Securities [Member] Corporate Debt Securities [Member] Financial Institution Instruments [Member] Financial Institution Instruments [Member] Information pertaining to financial institution instruments. Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Available-for-sale Securities Available-for-sale Securities Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Americas [Member] Americas [Member] HONG KONG HONG KONG CHINA CHINA TAIWAN, PROVINCE OF CHINA TAIWAN, PROVINCE OF CHINA KOREA, REPUBLIC OF KOREA, REPUBLIC OF JAPAN JAPAN SINGAPORE SINGAPORE MALAYSIA MALAYSIA Russia and Kazakhstan [Domain] Russia and Kazakhstan [Domain] Russia and Kazakhstan [Domain] Europe [Member] Europe [Member] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Sales Return Rate Sales Return Rate Sales Return Rate - percentage of sales refunded/returned Sales Revenue, Goods, Gross Sales Revenue, Goods, Gross Sales Revenue, Goods, Net Revenue Percentage Revenue Percentage revenue percentage by geographic location Shipping and Handling Revenue Shipping and Handling Revenue Sales Returns, Goods Sales Returns, Goods Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Broady Health Sciences Broady Health Sciences [Member] Represents Broady Health Sciences. Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] ReStore ReStore [Member] Represents a product called ReStore™. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Royalty rate Royalty Rate Represents the royalty rate. Royalty expense Royalty Expense Number of days for termination notice Number Of Days Termination Notice Represents number of days termination notice. Revenue [Text Block] Revenue [Text Block] Revenue [Text Block] Available-for-sale Securities [Table Text Block] Available-for-sale Securities [Table Text Block] INCOME TAXES [Abstract] INCOME TAXES [Abstract] GILTI provisional tax, net of foreign credits GILTI provisional tax, net of foreign credits GILTI provisional tax, net of foreign credits Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Inventories Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Deferred Tax Assets, Net, Current Deferred Tax Assets, Net, Current Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Income taxes payable Accrued Income Taxes, Current Accrued commissions Accrued Liabilities, Current Other accrued expenses Other Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Amounts held in eWallets Other Deferred Credits, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Accrued Income Taxes, Noncurrent Accrued Income Taxes, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Long-term incentive Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 9) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at March 31, 2018 and December 31, 2017 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Treasury stock, at cost; 1,603,322 and 1,637,524 shares at March 31, 2018 and December 31, 2017, respectively Treasury Stock, Value Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Enrollment Package Revenue [Member] Enrollment Package Revenue [Member] Represents enrollment package revenue. Auto Ship Advances [Member] Auto Ship Advances [Member] Represents Auto Ship advances. Unshipped Product [Member] Unshipped Product [Member] Represents unshipped product. Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash Equivalents [Member] Cash Equivalents [Member] Cash [Member] Cash [Member] Condensed Balance Sheet Statements, Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Cash and Cash Equivalents, at Carrying Value Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Inventory, Raw Materials and Supplies, Gross Inventory, Raw Materials and Supplies, Gross Inventory Valuation Reserves Inventory Valuation Reserves Inventory, Net Accrued Sales Returns Accrued Sales Returns Accrued Sales Returns Accrued Employee Benefits, Current Accrued Employee Benefits, Current Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Other Accrued Liabilities, Current Deferred Revenue Deferred Revenue Deferred Revenue, Current Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Securities Class Action Securities Class Action [Member] Securities Class Action [Member] shareholder derivative claim [Member] shareholder derivative claim [Member] shareholder derivative claim [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Litigation Settlement, Amount Litigation Settlement, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Weighted Average Number of Shares Outstanding, Basic Earnings Per Share, Basic Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Weighted Average Number of Shares Outstanding, Diluted EX-101.PRE 9 nhtc-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 nhtc20180502_10q_htm.xml IDEA: XBRL DOCUMENT 0000912061 2018-01-01 2018-03-31 0000912061 us-gaap:EuropeMember 2018-01-01 2018-03-31 0000912061 us-gaap:AmericasMember 2017-01-01 2017-03-31 0000912061 country:JP 2017-01-01 2017-03-31 0000912061 country:KR 2017-01-01 2017-03-31 0000912061 country:KR 2018-01-01 2018-03-31 0000912061 nhtc:RussiaandKazakhstanDomain 2018-01-01 2018-03-31 0000912061 country:SG 2018-01-01 2018-03-31 0000912061 us-gaap:EuropeMember 2017-01-01 2017-03-31 0000912061 country:HK 2018-01-01 2018-03-31 0000912061 country:HK 2017-01-01 2017-03-31 0000912061 2018-03-31 0000912061 country:MY 2017-01-01 2017-03-31 0000912061 country:TW 2018-01-01 2018-03-31 0000912061 us-gaap:AmericasMember 2018-01-01 2018-03-31 0000912061 country:JP 2018-01-01 2018-03-31 0000912061 country:CN 2017-01-01 2017-03-31 0000912061 nhtc:RussiaandKazakhstanDomain 2017-01-01 2017-03-31 0000912061 country:MY 2018-01-01 2018-03-31 0000912061 us-gaap:CashEquivalentsMember 2018-03-31 0000912061 us-gaap:CashMember 2017-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2018-03-31 0000912061 2017-12-31 0000912061 nhtc:AutoShipAdvancesMember 2018-03-31 0000912061 nhtc:UnshippedProductMember 2018-03-31 0000912061 nhtc:UnshippedProductMember 2017-12-31 0000912061 nhtc:AutoShipAdvancesMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember 2017-12-31 0000912061 us-gaap:CashMember 2018-03-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2017-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2018-03-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2018-03-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2017-12-31 0000912061 2017-01-01 2017-03-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2018-03-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2017-12-31 0000912061 2016-01-12 0000912061 us-gaap:RestrictedStockMember 2018-02-01 2018-02-01 0000912061 2018-02-06 2018-02-06 0000912061 2018-02-01 2018-02-01 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 2015-07-28 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000912061 2016-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-03-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-03-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-01-01 2018-03-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 2017-03-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-03-31 0000912061 nhtc:ShareholderderivativeclaimMember 2018-01-01 2018-03-31 0000912061 nhtc:SecuritiesClassActionMember 2018-01-01 2018-03-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-03-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2018-01-01 2018-03-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2013-02-01 2013-02-28 0000912061 us-gaap:SubsequentEventMember 2018-04-17 2018-04-17 0000912061 country:TW 2017-01-01 2017-03-31 0000912061 country:CN 2018-01-01 2018-03-31 0000912061 country:SG 2017-01-01 2017-03-31 pure shares iso4217:USD iso4217:USD shares utreg:Rate false --12-31 Q1 2018 0000912061 Yes Accelerated Filer 0.001 0.001 50000000 50000000 12979414 12979414 0.001 0.001 5000000 5000000 0 0 0 0 P3Y 1637524 1603322 10-Q 2018-03-31 NATURAL HEALTH TRENDS CORP. 11376092 145095000 135311000 7944000 8398000 6021000 7534000 159060000 151243000 1040000 1149000 1764000 1764000 3279000 3167000 1435000 1435000 809000 796000 167387000 159554000 2669000 1751000 42000 309000 10027000 11170000 8549000 7605000 4112000 4455000 14623000 15152000 1756000 1479000 41778000 41921000 19052000 19052000 55000 56000 7596000 7904000 68481000 68933000 0 0 13000 13000 86415000 86683000 52253000 44908000 -27000 -413000 39748000 40570000 98906000 90621000 167387000 159554000 52367000 59874000 10221000 11245000 42146000 48629000 22980000 25965000 9122000 9672000 32102000 35637000 10044000 12992000 163000 156000 10207000 13148000 1383000 2723000 8824000 10425000 0.78 0.93 0.78 0.93 11286000 11229000 11288000 11251000 0.13 0.44 8824000 10425000 397000 76000 0 258000 397000 -182000 -11000 -7000 9210000 10236000 8824000 10425000 131000 136000 0 9000 0 258000 -473000 -2091000 -1548000 -1419000 5000 62000 920000 -61000 -275000 1798000 -1119000 -428000 1483000 -1555000 -333000 -647000 -466000 1138000 272000 314000 -308000 -508000 11145000 13811000 17000 72000 -17000 -72000 1479000 4981000 -1479000 -4981000 247000 22000 9896000 8780000 138478000 128884000 148374000 137664000 554000 1393000 NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Operations</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 27, 2018.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span>, the Company has included amounts classified as restricted cash or restricted cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows. Principles of Consolidation<div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities had the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that began after December 15, 2017, including interim reporting periods. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 3 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements. REVENUE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, which was adopted on January 1, 2018 using the modified retrospective method. All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.  No material changes in estimates have been recognized during the periods presented. See Note 5 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue recognized which was included in deferred revenue as of December 31, 2017, offset by cash payments received or due in advance of satisfying the Company’s performance obligations. See Note 5 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth revenue by market for the periods indicated (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Americas</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,259</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,754</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Singapore</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Malaysia</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia and Kazakhstan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,367</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,874</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States, Canada, Mexico and Peru</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by product and service are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,365</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,367</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,874</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No single market other than Hong Kong had net sales greater than 10% of total net sales and no single customer accounted for 10% or more of net sales for the three months ended March 31, 2018 and 2017. The Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Arrangements with Multiple Performance Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Practical Expedients</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less. Revenue Recognition<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, which was adopted on January 1, 2018 using the modified retrospective method. All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.  No material changes in estimates have been recognized during the periods presented. See Note 5 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div>Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. 0.02 3200000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Americas</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,259</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,754</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Singapore</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Malaysia</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia and Kazakhstan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,367</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,874</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div> 1536000 0.029 1460000 0.024 47619000 0.910 54567000 0.911 1259000 0.024 1754000 0.029 1061000 0.020 1158000 0.020 119000 0.002 122000 0.002 65000 0.001 27000 0 31000 0.001 45000 0.001 43000 0.001 0 0 203000 0.004 217000 0.004 431000 0.008 524000 0.009 52367000 1.000 59874000 1.000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,365</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,367</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,874</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 49365000 56577000 3752000 4636000 750000 1339000 52367000 59874000 NET INCOME PER COMMON SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.78</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.78</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Certain</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>28,747</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">shares were not included for the three months ended March 31, 2018.</span> Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.78</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.78</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8824000 11286000 0.78 10425000 11229000 0.93 2000 22000 8824000 11288000 0.78 10425000 11251000 0.93 28747 BALANCE SHEET COMPONENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of certain balance sheet amounts are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,846</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">145,095</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">135,311</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,279</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,779</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The components of certain balance sheet amounts are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,846</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">145,095</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">135,311</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,279</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,779</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 70249000 61703000 74846000 73608000 3279000 3167000 148374000 138478000 7524000 7779000 572000 799000 152000 180000 7944000 8398000 689000 614000 5316000 5568000 2544000 1423000 8549000 7605000 2017000 2411000 1740000 1665000 355000 379000 4112000 4455000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,155</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,075</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,039</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,846</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits. As of <span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets. Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,155</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,075</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,039</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,846</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 5155000 -1000 5154000 13320000 -1000 13319000 54075000 -36000 54039000 49432000 -24000 49408000 15653000 0 15653000 10881000 0 10881000 74883000 -37000 74846000 73633000 -25000 73608000 STOCKHOLDERS’ EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 6, 2018, the Board of Directors declared a cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.13</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends were paid on March 9, 2018 to stockholders of record on February 27, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No stock-based compensation was recognized for the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Stock-based compensation expense totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$8,700</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2,359,671</span></span><span style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2016 Plan. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2018, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>34,202</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2017 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$554,000</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at March 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in accumulated other comprehensive loss by component for the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of 2018 were as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>386</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, March 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> 0.13 15000000.0 70000000.0 32000000.0 70000000.0 8700 2500000 2359671 34202 554000 The following table summarizes the Company’s restricted stock activity under the 2016 Plan:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at March 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 58032 28.59 34202 16.19 11687 26.31 80547 23.65 The changes in accumulated other comprehensive loss by component for the first <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of 2018 were as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>386</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, March 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> -386000 -27000 -413000 397000 -11000 386000 11000 -38000 -27000 INCOME TAXES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective income tax rate for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was significantly impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which affected the Company’s year ended December 31, 2017, including, but not limited to, reducing the maximum U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018, and requiring a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings, which is payable over eight years beginning with 8% of the liability due with the filing of the year ended December 31, 2017 federal tax return that will be due in 2018. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in the corporate income tax rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in the Company’s interpretations and assumptions, additional guidance that may be issued by the Internal Revenue Service, and actions it may take. The Company is continuing to gather additional information to determine the final impact. Any adjustments recorded to the provisional amounts through the fourth quarter of 2018 will be included as an adjustment to income tax expense.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company is subject to the new Global Intangible Low-Taxed Income (“GILTI”) tax rules. GILTI is the excess income of foreign subsidiaries over a 10% routine return on tangible assets. After a 50% deduction, GILTI is subject to the 21% corporate tax rate. Due to the complexity of the GILTI tax rules, the Company continues to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, the Company is allowed to make an accounting policy choice of either treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or factoring such amounts into the Company’s measurement of its deferred taxes (the “deferred method”). Although the Company has not elected an accounting policy, it has recorded a provisional amount of the GILTI tax as a current period expense for 2018. The impact of GILTI on the effective tax rate for the three months ended March 31, 2018 was approximately 10%, or </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of foreign tax credits attributed to GILTI. The Company will determine the appropriate accounting policy for its structure and record any necessary adjustments within the measurement period.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. Due to the adoption of a territorial tax regime upon the enactment of the Tax Act, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on the Company’s effective tax rate. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of March 31, 2018, the Company has accrued tax liabilities for earnings that it plans to repatriate out of accumulated earnings in future periods for state tax purposes only. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of March 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2016 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2012. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries except that the Taiwan Taxation Administration is currently examining the Taiwan subsidiary’s 2016 tax return. No material adjustment is anticipated. 1000000.0 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. On April 2, 2018, the court approved a class-wide settlement of the action in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.75 million</span></span><span style="font-family:inherit;font-size:10pt;">, which will be fully funded by the Company’s insurers. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China, and it has made materially false and misleading statements regarding the legality of its business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> action pending conclusion of the related federal class action in the United States District Court for the Central District of California:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;"> A nearly identical stipulated stay was entered in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> case on February 28, 2017. On November 10, 2017, the parties to both the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> court entered an order continuing the stay on November 17, 2017.  On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> action. On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement.  On April 4, 2018, the court entered an order preliminarily approving the proposed settlement and setting a final hearing for July 16, 2018. If final approval is granted, the proposed settlement will require certain corporate governance reforms and permit an award of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement does not become final. If the proposed settlement is not finalized, the Derivative Complaints could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Claims</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor. 1750000 250000 RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor™</span><span style="font-family:inherit;font-size:10pt;">. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were </span><span style="font-family:inherit;font-size:10pt;"><span>$83,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$91,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">’ notice or, under certain circumstances, with </span><span style="font-family:inherit;font-size:10pt;">no</span> notice. Otherwise, the agreement terminates March 31, 2020. 0.025 83000 91000 P120D SUBSEQUENT EVENT<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">April 17, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.14</span></span><span style="font-family:inherit;font-size:10pt;"> and a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.76</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends are payable on </span><span style="font-family:inherit;font-size:10pt;">May 25, 2018</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">May 15, 2018</span>. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors. 0.14 1.76 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information
3 Months Ended
Mar. 31, 2018
shares
Document And Entity Information  
Document Type 10-Q
Document Period End Date Mar. 31, 2018
Entity Registrant Name NATURAL HEALTH TRENDS CORP.
Entity Central Index Key 0000912061
Current Fiscal Year End Date --12-31
Entity Filer Category Accelerated Filer
Entity Current Reporting Status Yes
Entity Common Stock, Shares Outstanding (in shares) 11,376,092
Document Fiscal Year Focus 2018
Document Fiscal Period Focus Q1
Amendment Flag false
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 145,095 $ 135,311
Inventories 7,944 8,398
Other current assets 6,021 7,534
Total current assets 159,060 151,243
Property and equipment, net 1,040 1,149
Goodwill 1,764 1,764
Restricted cash 3,279 3,167
Deferred Tax Assets, Net, Current 1,435 1,435
Other assets 809 796
Total assets 167,387 159,554
Current liabilities:    
Accounts payable 2,669 1,751
Income taxes payable 42 309
Accrued commissions 10,027 11,170
Other accrued expenses 8,549 7,605
Deferred revenue 4,112 4,455
Amounts held in eWallets 14,623 15,152
Other current liabilities 1,756 1,479
Total current liabilities 41,778 41,921
Accrued Income Taxes, Noncurrent 19,052 19,052
Deferred Tax Liabilities, Net, Noncurrent 55 56
Long-term incentive 7,596 7,904
Total liabilities 68,481 68,933
Commitments and contingencies (Note 9)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at March 31, 2018 and December 31, 2017 13 13
Additional paid-in capital 86,415 86,683
Retained earnings 52,253 44,908
Accumulated other comprehensive loss (27) (413)
Treasury stock, at cost; 1,603,322 and 1,637,524 shares at March 31, 2018 and December 31, 2017, respectively (39,748) (40,570)
Total stockholders’ equity 98,906 90,621
Total liabilities and stockholders’ equity $ 167,387 $ 159,554
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 12,979,414 12,979,414
Treasury stock, shares 1,603,322 1,637,524
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Net sales $ 52,367 $ 59,874
Cost of sales 10,221 11,245
Gross profit 42,146 48,629
Operating expenses:    
Commissions expense 22,980 25,965
Selling, general and administrative expenses 9,122 9,672
Total operating expenses 32,102 35,637
Income from operations 10,044 12,992
Other income, net 163 156
Income before income taxes 10,207 13,148
Income tax provision 1,383 2,723
Net income $ 8,824 $ 10,425
Net income per common share:    
Basic (in dollars per share) $ 0.78 $ 0.93
Earnings Per Share, Diluted $ 0.78 $ 0.93
Weighted-average number of common shares outstanding:    
Basic (in shares) 11,286 11,229
Diluted (in shares) 11,288 11,251
Cash dividends declared per share:    
Common (in dollars per share) $ 0.13 $ 0.44
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Statement of Comprehensive Income [Abstract]    
Net income $ 8,824 $ 10,425
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustment 397 76
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax 0 258
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax 397 (182)
Unrealized losses on available-for-sale securities (11) (7)
Comprehensive income $ 9,210 $ 10,236
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 8,824 $ 10,425
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 131 136
Stock-based compensation 0 9
Cumulative Translation Adjustment Realized In Net Income 0 (258)
Changes in assets and liabilities:    
Inventories 473 2,091
Other current assets 1,548 1,419
Other assets (5) (62)
Accounts payable 920 (61)
Income taxes payable (275) 1,798
Accrued commissions (1,119) (428)
Other accrued expenses 1,483 (1,555)
Deferred revenue (333) (647)
Amounts held in eWallets (466) 1,138
Other current liabilities 272 314
Long-term incentive (308) (508)
Net cash provided by operating activities 11,145 13,811
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (17) (72)
Net cash used in investing activities (17) (72)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Dividends paid (1,479) (4,981)
Net cash used in financing activities (1,479) (4,981)
Effect of exchange rates on cash, cash equivalents and restricted cash 247 22
Net increase in cash, cash equivalents and restricted cash 9,896 8,780
Cash 148,374 137,664
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 145,095  
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Issuance of treasury stock for employee awards, net $ 554 $ 1,393
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS AND BASIS OF PRESENTATION NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

Nature of Operations 
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 27, 2018.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

Reclassification

In accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, the Company has included amounts classified as restricted cash or restricted cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS (Notes)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block] ACCOUNTING PRONOUNCEMENTS
 
In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities had the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that began after December 15, 2017, including interim reporting periods. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 3 for additional information.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE Revenue (Notes)
3 Months Ended
Mar. 31, 2018
Revenue Recognition [Abstract]  
Revenue [Text Block] REVENUE

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts With Customers, which was adopted on January 1, 2018 using the modified retrospective method. All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were 2% of sales for the three months ended March 31, 2018 and 2017.  No material changes in estimates have been recognized during the periods presented. See Note 5 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended March 31, 2018 is primarily due to $3.2 million of revenue recognized which was included in deferred revenue as of December 31, 2017, offset by cash payments received or due in advance of satisfying the Company’s performance obligations. See Note 5 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider.

The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended March 31,
 
2018
 
2017
Americas1
$
1,536

 
2.9
%
 
$
1,460

 
2.4
%
Hong Kong2
47,619

 
91.0

 
54,567

 
91.1

China
1,259

 
2.4

 
1,754

 
2.9

Taiwan
1,061

 
2.0

 
1,158

 
2.0

South Korea
119

 
0.2

 
122

 
0.2

Japan
65

 
0.1

 
27

 

Singapore
31

 
0.1

 
45

 
0.1

Malaysia
43

 
0.1

 

 

Russia and Kazakhstan
203

 
0.4

 
217

 
0.4

Europe
431

 
0.8

 
524

 
0.9

Total
$
52,367

 
100.0
%
 
$
59,874

 
100.0
%

1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K.

The Company’s net sales by product and service are as follows (in thousands):
 
Three Months Ended March 31,
 
2018
 
2017
Product sales
$
49,365

 
$
56,577

Freight and other
3,752

 
4,636

Less: sales returns
(750
)
 
(1,339
)
Total net sales
$
52,367

 
$
59,874



Concentration

No single market other than Hong Kong had net sales greater than 10% of total net sales and no single customer accounted for 10% or more of net sales for the three months ended March 31, 2018 and 2017. The Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block] NET INCOME PER COMMON SHARE

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended March 31,
 
2018
 
2017
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
8,824

 
11,286

 
$
0.78

 
$
10,425

 
11,229

 
$
0.93

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
2

 
 

 

 
22

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
8,824

 
11,288

 
$
0.78

 
$
10,425

 
11,251

 
$
0.93


Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling 28,747 shares were not included for the three months ended March 31, 2018.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
BALANCE SHEET COMPONENTS Balance Sheet Components
3 Months Ended
Mar. 31, 2018
Balance Sheet Components [Abstract]  
Supplemental Balance Sheet Disclosures [Text Block] BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
March 31, 2018
 
December 31, 2017
Cash, cash equivalents and restricted cash:
 
 
 
Cash
$
70,249

 
$
61,703

Cash equivalents
74,846

 
73,608

 
145,095

 
135,311

Restricted cash
3,279

 
3,167

 
$
148,374

 
$
138,478

Inventories:
 
 
 
Finished goods
$
7,524

 
$
7,779

Raw materials
572

 
799

Inventory reserve for obsolescence
(152
)
 
(180
)
 
$
7,944

 
$
8,398

Other accrued expenses:
 
 
 
Sales returns
$
689

 
$
614

Employee-related expense
5,316

 
5,568

Warehousing, inventory-related and other
2,544

 
1,423

 
$
8,549

 
$
7,605

Deferred revenue:
 
 
 
Unshipped product
$
2,017

 
$
2,411

Auto ship advances
1,740

 
1,665

Other
355

 
379

 
$
4,112

 
$
4,455

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENTS (Notes)
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS

As of March 31, 2018, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at March 31, 2018 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
March 31, 2018
 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Municipal bonds and notes
$
5,155

 
$
(1
)
 
$
5,154

 
$
13,320

 
$
(1
)
 
$
13,319

Corporate debt securities
54,075

 
(36
)
 
54,039

 
49,432

 
(24
)
 
49,408

Financial institution instruments
15,653

 

 
15,653

 
10,881

 

 
10,881

Total available-for-sale investments
$
74,883

 
$
(37
)
 
$
74,846

 
$
73,633

 
$
(25
)
 
$
73,608


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDERS' EQUITY
3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS’ EQUITY
 
Dividends

On February 6, 2018, the Board of Directors declared a cash dividend of $0.13 on each share of common stock outstanding. Such dividends were paid on March 9, 2018 to stockholders of record on February 27, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of March 31, 2018, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

No stock-based compensation was recognized for the three months ended March 31, 2018. Stock-based compensation expense totaled $8,700 for the three months ended March 31, 2017.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At March 31, 2018, 2,359,671 shares remained available for issuance under the 2016 Plan.

On February 1, 2018, the Company granted 34,202 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2017 performance incentives totaling $554,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2017
58,032

 
$
28.59

Granted
34,202

 
16.19

Vested
(11,687
)
 
26.31

Nonvested at March 31, 2018
80,547

 
23.65



Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first three months of 2018 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2017
$
(386
)
 
$
(27
)
 
$
(413
)
Other comprehensive income (loss)
397

 
(11
)
 
386

Balance, March 31, 2018
$
11

 
$
(38
)
 
$
(27
)
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
INCOME TAXES INCOME TAXES
3 Months Ended
Mar. 31, 2018
INCOME TAXES [Abstract]  
Income Tax, Policy [Policy Text Block] INCOME TAXES

The effective income tax rate for the three months ended March 31, 2018 was significantly impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which affected the Company’s year ended December 31, 2017, including, but not limited to, reducing the maximum U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018, and requiring a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings, which is payable over eight years beginning with 8% of the liability due with the filing of the year ended December 31, 2017 federal tax return that will be due in 2018.

On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in the corporate income tax rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in the Company’s interpretations and assumptions, additional guidance that may be issued by the Internal Revenue Service, and actions it may take. The Company is continuing to gather additional information to determine the final impact. Any adjustments recorded to the provisional amounts through the fourth quarter of 2018 will be included as an adjustment to income tax expense.

Effective January 1, 2018, the Company is subject to the new Global Intangible Low-Taxed Income (“GILTI”) tax rules. GILTI is the excess income of foreign subsidiaries over a 10% routine return on tangible assets. After a 50% deduction, GILTI is subject to the 21% corporate tax rate. Due to the complexity of the GILTI tax rules, the Company continues to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, the Company is allowed to make an accounting policy choice of either treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or factoring such amounts into the Company’s measurement of its deferred taxes (the “deferred method”). Although the Company has not elected an accounting policy, it has recorded a provisional amount of the GILTI tax as a current period expense for 2018. The impact of GILTI on the effective tax rate for the three months ended March 31, 2018 was approximately 10%, or $1.0 million, net of foreign tax credits attributed to GILTI. The Company will determine the appropriate accounting policy for its structure and record any necessary adjustments within the measurement period.

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. Due to the adoption of a territorial tax regime upon the enactment of the Tax Act, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on the Company’s effective tax rate. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of March 31, 2018, the Company has accrued tax liabilities for earnings that it plans to repatriate out of accumulated earnings in future periods for state tax purposes only. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of March 31, 2018.

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2016 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2012. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries except that the Taiwan Taxation Administration is currently examining the Taiwan subsidiary’s 2016 tax return. No material adjustment is anticipated.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES

Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. On April 2, 2018, the court approved a class-wide settlement of the action in the amount of $1.75 million, which will be fully funded by the Company’s insurers. 

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China, and it has made materially false and misleading statements regarding the legality of its business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies.

On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the Zhou matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The Zhou court entered an order continuing the stay on November 17, 2017.  On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the Kleinfeldt action. On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement.  On April 4, 2018, the court entered an order preliminarily approving the proposed settlement and setting a final hearing for July 16, 2018. If final approval is granted, the proposed settlement will require certain corporate governance reforms and permit an award of up to $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement does not become final. If the proposed settlement is not finalized, the Derivative Complaints could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

Other Claims

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2018
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS

In February 2013, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were $83,000 and $91,000 for the three months ended March 31, 2018 and 2017, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUBSEQUENT EVENT
3 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENT SUBSEQUENT EVENT
 
On April 17, 2018, the Board of Directors declared a quarterly cash dividend of $0.14 and a special cash dividend of $1.76 on each share of common stock outstanding. Such dividends are payable on May 25, 2018 to stockholders of record on May 15, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION
3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of Consolidation Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block] ACCOUNTING PRONOUNCEMENTS
 
In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities had the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that began after December 15, 2017, including interim reporting periods. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 3 for additional information.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE Revenue Recognition (Policies)
3 Months Ended
Mar. 31, 2018
Revenue Recognition [Abstract]  
Revenue Recognition, Policy [Policy Text Block] Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts With Customers, which was adopted on January 1, 2018 using the modified retrospective method. All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were 2% of sales for the three months ended March 31, 2018 and 2017.  No material changes in estimates have been recognized during the periods presented. See Note 5 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Earnings Per Share, Policy [Policy Text Block] Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENTS (Policies)
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Cash and Cash Equivalents, Policy [Policy Text Block] As of March 31, 2018, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at March 31, 2018 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.
Fair Value of Financial Instruments, Policy [Policy Text Block] The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE Revenue (Tables)
3 Months Ended
Mar. 31, 2018
Revenue Recognition [Abstract]  
Revenue from External Customers by Geographic Areas [Table Text Block]
 
Three Months Ended March 31,
 
2018
 
2017
Americas1
$
1,536

 
2.9
%
 
$
1,460

 
2.4
%
Hong Kong2
47,619

 
91.0

 
54,567

 
91.1

China
1,259

 
2.4

 
1,754

 
2.9

Taiwan
1,061

 
2.0

 
1,158

 
2.0

South Korea
119

 
0.2

 
122

 
0.2

Japan
65

 
0.1

 
27

 

Singapore
31

 
0.1

 
45

 
0.1

Malaysia
43

 
0.1

 

 

Russia and Kazakhstan
203

 
0.4

 
217

 
0.4

Europe
431

 
0.8

 
524

 
0.9

Total
$
52,367

 
100.0
%
 
$
59,874

 
100.0
%
Revenue from External Customers by Products and Services [Table Text Block]
 
Three Months Ended March 31,
 
2018
 
2017
Product sales
$
49,365

 
$
56,577

Freight and other
3,752

 
4,636

Less: sales returns
(750
)
 
(1,339
)
Total net sales
$
52,367

 
$
59,874

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended March 31,
 
2018
 
2017
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
8,824

 
11,286

 
$
0.78

 
$
10,425

 
11,229

 
$
0.93

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
2

 
 

 

 
22

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
8,824

 
11,288

 
$
0.78

 
$
10,425

 
11,251

 
$
0.93


XML 35 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)
3 Months Ended
Mar. 31, 2018
Balance Sheet Components [Abstract]  
Schedule of Additional Balance Sheet Components [Table Text Block] The components of certain balance sheet amounts are as follows (in thousands):
 
March 31, 2018
 
December 31, 2017
Cash, cash equivalents and restricted cash:
 
 
 
Cash
$
70,249

 
$
61,703

Cash equivalents
74,846

 
73,608

 
145,095

 
135,311

Restricted cash
3,279

 
3,167

 
$
148,374

 
$
138,478

Inventories:
 
 
 
Finished goods
$
7,524

 
$
7,779

Raw materials
572

 
799

Inventory reserve for obsolescence
(152
)
 
(180
)
 
$
7,944

 
$
8,398

Other accrued expenses:
 
 
 
Sales returns
$
689

 
$
614

Employee-related expense
5,316

 
5,568

Warehousing, inventory-related and other
2,544

 
1,423

 
$
8,549

 
$
7,605

Deferred revenue:
 
 
 
Unshipped product
$
2,017

 
$
2,411

Auto ship advances
1,740

 
1,665

Other
355

 
379

 
$
4,112

 
$
4,455

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Available-for-sale Securities [Table Text Block] Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
March 31, 2018
 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Municipal bonds and notes
$
5,155

 
$
(1
)
 
$
5,154

 
$
13,320

 
$
(1
)
 
$
13,319

Corporate debt securities
54,075

 
(36
)
 
54,039

 
49,432

 
(24
)
 
49,408

Financial institution instruments
15,653

 

 
15,653

 
10,881

 

 
10,881

Total available-for-sale investments
$
74,883

 
$
(37
)
 
$
74,846

 
$
73,633

 
$
(25
)
 
$
73,608

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)
3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Restricted Stock Activity The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2017
58,032

 
$
28.59

Granted
34,202

 
16.19

Vested
(11,687
)
 
26.31

Nonvested at March 31, 2018
80,547

 
23.65

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
3 Months Ended
Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] The changes in accumulated other comprehensive loss by component for the first three months of 2018 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2017
$
(386
)
 
$
(27
)
 
$
(413
)
Other comprehensive income (loss)
397

 
(11
)
 
386

Balance, March 31, 2018
$
11

 
$
(38
)
 
$
(27
)
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenue from External Customer [Line Items]    
Sales Return Rate 2.00%  
Sales Revenue, Goods, Gross $ 49,365 $ 56,577
Sales Revenue, Goods, Net $ 52,367 $ 59,874
Revenue Percentage 100.00% 100.00%
Shipping and Handling Revenue $ 3,752 $ 4,636
Sales Returns, Goods (750) (1,339)
Deferred Revenue, Revenue Recognized 3,200  
Americas [Member]    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 1,536 $ 1,460
Revenue Percentage 2.90% 2.40%
HONG KONG    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 47,619 $ 54,567
Revenue Percentage 91.00% 91.10%
CHINA    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 1,259 $ 1,754
Revenue Percentage 2.40% 2.90%
TAIWAN, PROVINCE OF CHINA    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 1,061 $ 1,158
Revenue Percentage 2.00% 2.00%
KOREA, REPUBLIC OF    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 119 $ 122
Revenue Percentage 0.20% 0.20%
JAPAN    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 65 $ 27
Revenue Percentage 0.10% 0.00%
SINGAPORE    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 31 $ 45
Revenue Percentage 0.10% 0.10%
MALAYSIA    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 43 $ 0
Revenue Percentage 0.10% 0.00%
Russia and Kazakhstan [Domain]    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 203 $ 217
Revenue Percentage 0.40% 0.40%
Europe [Member]    
Revenue from External Customer [Line Items]    
Sales Revenue, Goods, Net $ 431 $ 524
Revenue Percentage 0.80% 0.90%
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Earnings Per Share [Abstract]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 28,747  
Net Income (Loss) Available to Common Stockholders, Basic $ 8,824 $ 10,425
Weighted Average Number of Shares Outstanding, Basic 11,286,000 11,229,000
Earnings Per Share, Basic $ 0.78 $ 0.93
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 2,000 22,000
Net Income (Loss) Available to Common Stockholders, Diluted $ 8,824 $ 10,425
Weighted Average Number of Shares Outstanding, Diluted 11,288,000 11,251,000
Earnings Per Share, Diluted $ 0.78 $ 0.93
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
BALANCE SHEET COMPONENTS Balance Sheet Components (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Dec. 31, 2016
Condensed Balance Sheet Statements, Captions [Line Items]        
Cash and Cash Equivalents, at Carrying Value $ 145,095 $ 135,311    
Restricted cash 3,279 3,167    
Cash 148,374 138,478 $ 137,664 $ 128,884
Inventory, Finished Goods, Gross 7,524 7,779    
Inventory, Raw Materials and Supplies, Gross 572 799    
Inventory Valuation Reserves (152) (180)    
Inventory, Net 7,944 8,398    
Accrued Sales Returns 689 614    
Accrued Employee Benefits, Current 5,316 5,568    
Accrued Warehousing And Inventory Related Expense 2,544 1,423    
Other Accrued Liabilities, Current 8,549 7,605    
Deferred Revenue, Current 4,112 4,455    
Cash Equivalents [Member]        
Condensed Balance Sheet Statements, Captions [Line Items]        
Cash and Cash Equivalents, at Carrying Value 74,846 73,608    
Cash [Member]        
Condensed Balance Sheet Statements, Captions [Line Items]        
Cash and Cash Equivalents, at Carrying Value 70,249 61,703    
Enrollment Package Revenue [Member]        
Condensed Balance Sheet Statements, Captions [Line Items]        
Deferred Revenue 355 379    
Auto Ship Advances [Member]        
Condensed Balance Sheet Statements, Captions [Line Items]        
Deferred Revenue 1,740 1,665    
Unshipped Product [Member]        
Condensed Balance Sheet Statements, Captions [Line Items]        
Deferred Revenue $ 2,017 $ 2,411    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENTS (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis $ 74,883 $ 73,633
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (37) (25)
Available-for-sale Securities 74,846 73,608
Municipal Bonds and Notes [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 5,155 13,320
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (1) (1)
Available-for-sale Securities 5,154 13,319
Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 54,075 49,432
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (36) (24)
Available-for-sale Securities 54,039 49,408
Financial Institution Instruments [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 15,653 10,881
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax 0 0
Available-for-sale Securities $ 15,653 $ 10,881
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDERS' EQUITY NARRATIVE (Details) - USD ($)
3 Months Ended
Feb. 06, 2018
Feb. 01, 2018
Mar. 31, 2018
Mar. 31, 2017
Apr. 07, 2016
Jan. 12, 2016
Jul. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common Stock, Dividends, Per Share, Declared     $ 0.13 $ 0.44      
Share-based compensation expense       $ 8,700      
Stock repurchase program, amount authorized           $ 70,000,000.0 $ 15,000,000.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount     $ 32,000,000.0        
Common Stock, Dividends, Per Share, Cash Paid $ 0.13            
Restricted Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Granted (in shares)   34,202          
Award vesting period (in years)   3 years          
Equity Incentive Plan 2016 | Common Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares authorized         2,500,000    
Equity Incentive Plan 2016 | Restricted Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Granted (in shares)     34,202        
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Feb. 01, 2018
Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant   2,359,671
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Stock Issued During Period, Value, Restricted Stock Award, Gross $ 554  
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Granted (in shares) 34,202  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 3 years  
Restricted Stock | Equity Incentive Plan 2016    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Nonvested, beginning balance (in shares)   58,032
Granted (in shares)   34,202
Vested (in shares)   (11,687)
Nonvested, ending balance (in shares)   80,547
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested, beginning balance (in dollars per share)   $ 28.59
Granted (in dollars per share)   16.19
Vested (in dollars per share)   26.31
Nonvested, ending balance (in dollars per share)   $ 23.65
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2018
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 $ (413)
Balance, March 31, 2018 (27)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 (386)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 397
Balance, March 31, 2018 11
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 (27)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (11)
Balance, March 31, 2018 (38)
AOCI Attributable to Parent [Member]  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 (413)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 386
Balance, March 31, 2018 $ (27)
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
INCOME TAXES NARRATIVE (Details)
$ in Millions
3 Months Ended
Mar. 31, 2018
USD ($)
INCOME TAXES [Abstract]  
GILTI provisional tax, net of foreign credits $ 1.0
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2018
USD ($)
Securities Class Action  
Loss Contingencies [Line Items]  
Litigation Settlement, Amount $ 1,750
shareholder derivative claim [Member]  
Loss Contingencies [Line Items]  
Litigation Settlement, Amount $ 250
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
RELATED PARTY TRANSACTIONS NARRATIVE (Detail) - Broady Health Sciences - ReStore - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Feb. 28, 2013
Mar. 31, 2018
Mar. 31, 2017
Related Party Transaction [Line Items]      
Royalty rate 2.50%    
Royalty expense   $ 83 $ 91
Number of days for termination notice 120 days    
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUBSEQUENT EVENT - NARRATIVE (Details) - $ / shares
3 Months Ended
Apr. 17, 2018
Mar. 31, 2018
Mar. 31, 2017
Subsequent Event [Line Items]      
Common Stock, Dividends, Per Share, Declared   $ 0.13 $ 0.44
Subsequent Event      
Subsequent Event [Line Items]      
Common Stock, Dividends, Per Share, Declared $ 0.14    
CommonStockSpecialDividendsPerShareDeclared $ 1.76    
EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 66 158 1 false 29 0 false 5 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1002000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 5 false false R6.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 2107100 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS (Notes) Notes http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncementsNotes ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS (Notes) Notes 8 false false R9.htm 2108100 - Disclosure - REVENUE Revenue (Notes) Notes http://www.naturalhealthtrendscorp.com/role/RevenueRevenueNotes REVENUE Revenue (Notes) Notes 9 false false R10.htm 2110100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE Notes 10 false false R11.htm 2111100 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents BALANCE SHEET COMPONENTS Balance Sheet Components Notes 11 false false R12.htm 2112100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes) Notes http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes FAIR VALUE MEASUREMENTS (Notes) Notes 12 false false R13.htm 2113100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 2114100 - Disclosure - INCOME TAXES INCOME TAXES Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes INCOME TAXES INCOME TAXES Notes 14 false false R15.htm 2115100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 2116100 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 2117100 - Disclosure - SUBSEQUENT EVENT Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 17 false false R18.htm 2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION Notes 18 false false R19.htm 2207201 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS Sheet http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS Notes 19 false false R20.htm 2208201 - Disclosure - REVENUE Revenue Recognition (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueRevenueRecognitionPolicies REVENUE Revenue Recognition (Policies) Policies 20 false false R21.htm 2210201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies) Policies 21 false false R22.htm 2212201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies FAIR VALUE MEASUREMENTS (Policies) Policies 22 false false R23.htm 2308302 - Disclosure - REVENUE Revenue (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueRevenueTables REVENUE Revenue (Tables) Tables http://www.naturalhealthtrendscorp.com/role/RevenueRevenueNotes 23 false false R24.htm 2310302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables) Tables 24 false false R25.htm 2311301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables BALANCE SHEET COMPONENTS Balance Sheet Components (Tables) Tables http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents 25 false false R26.htm 2312302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes 26 false false R27.htm 2313301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables) Tables 27 false false R28.htm 2313302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Tables 28 false false R29.htm 2408403 - Disclosure - REVENUE Revenue (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails REVENUE Revenue (Details) Details http://www.naturalhealthtrendscorp.com/role/RevenueRevenueTables 29 false false R30.htm 2410403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) Details http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables 30 false false R31.htm 2411402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails BALANCE SHEET COMPONENTS Balance Sheet Components (Details) Details http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables 31 false false R32.htm 2412403 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables 32 false false R33.htm 2413403 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails STOCKHOLDERS' EQUITY NARRATIVE (Details) Details 33 false false R34.htm 2413404 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) Details http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables 34 false false R35.htm 2413405 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Details http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables 35 false false R36.htm 2414401 - Disclosure - INCOME TAXES NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails INCOME TAXES NARRATIVE (Details) Details 36 false false R37.htm 2415401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES NARRATIVE (Details) Details 37 false false R38.htm 2416401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail) Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail RELATED PARTY TRANSACTIONS NARRATIVE (Detail) Details 38 false false R39.htm 2417401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails SUBSEQUENT EVENT - NARRATIVE (Details) Details 39 false false All Reports Book All Reports nhtc20180502_10q.htm ex31-1.htm ex31-2.htm ex32-1.htm nhtc-20180331.xsd nhtc-20180331_cal.xml nhtc-20180331_def.xml nhtc-20180331_lab.xml nhtc-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2016-01-31 http://xbrl.sec.gov/country/2016-01-31 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20180502_10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 66, "dts": { "calculationLink": { "local": [ "nhtc-20180331_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20180331_def.xml" ] }, "inline": { "local": [ "nhtc20180502_10q.htm" ] }, "labelLink": { "local": [ "nhtc-20180331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20180331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml" ] }, "schema": { "local": [ "nhtc-20180331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd", "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd", "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 263, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2016-01-31": 17, "http://xbrl.sec.gov/dei/2014-01-31": 7, "total": 24 }, "keyCustom": 11, "keyStandard": 147, "memberCustom": 11, "memberStandard": 18, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare", "shortName": "NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents", "shortName": "BALANCE SHEET COMPONENTS Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes", "shortName": "FAIR VALUE MEASUREMENTS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - INCOME TAXES INCOME TAXES", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes", "shortName": "INCOME TAXES INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - SUBSEQUENT EVENT", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation", "shortName": "NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2207201 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS", "role": "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements", "shortName": "ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q1", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2208201 - Disclosure - REVENUE Revenue Recognition (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueRecognitionPolicies", "shortName": "REVENUE Revenue Recognition (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2210201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies", "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2212201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies", "shortName": "FAIR VALUE MEASUREMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - REVENUE Revenue (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueTables", "shortName": "REVENUE Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables", "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables", "shortName": "BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables", "shortName": "STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables", "shortName": "STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "2", "first": true, "lang": null, "name": "nhtc:SalesReturnRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - REVENUE Revenue (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails", "shortName": "REVENUE Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "2", "first": true, "lang": null, "name": "nhtc:SalesReturnRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails", "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "shortName": "BALANCE SHEET COMPONENTS Balance Sheet Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "shortName": "STOCKHOLDERS' EQUITY NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q1QTD", "decimals": "-2", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413404 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "shortName": "STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "shortName": "STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "nhtc:GILTIprovisionaltaxnetofforeigncredits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - INCOME TAXES NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "shortName": "INCOME TAXES NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "nhtc:GILTIprovisionaltaxnetofforeigncredits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail)", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail", "shortName": "RELATED PARTY TRANSACTIONS NARRATIVE (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails", "shortName": "SUBSEQUENT EVENT - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation", "shortName": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS (Notes)", "role": "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncementsNotes", "shortName": "ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS (Notes)", "subGroupType": "", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:RevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - REVENUE Revenue (Notes)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueNotes", "shortName": "REVENUE Revenue (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:RevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 29, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "HONG KONG", "terseLabel": "HONG KONG" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "JAPAN", "terseLabel": "JAPAN" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "KOREA, REPUBLIC OF" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "country_MY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MALAYSIA", "terseLabel": "MALAYSIA" } } }, "localname": "MY", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "country_SG": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SINGAPORE", "terseLabel": "SINGAPORE" } } }, "localname": "SG", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TAIWAN, PROVINCE OF CHINA", "terseLabel": "TAIWAN, PROVINCE OF CHINA" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Sales Returns", "label": "Accrued Sales Returns", "terseLabel": "Accrued Sales Returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Warehousing And Inventory Related Expense", "label": "Accrued Warehousing And Inventory Related Expense", "terseLabel": "Accrued Warehousing And Inventory Related Expense" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccumulatedOtherComprehensiveLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Loss [Abstract]", "label": "Accumulated Other Comprehensive Loss [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveLossAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "xbrltype": "stringItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Auto Ship advances.", "label": "Auto Ship Advances [Member]", "terseLabel": "Auto Ship Advances [Member]" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_BalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components [Abstract]" } } }, "localname": "BalanceSheetComponentsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "xbrltype": "stringItemType" }, "nhtc_BroadyHealthSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Broady Health Sciences.", "label": "Broady Health Sciences [Member]", "terseLabel": "Broady Health Sciences" } } }, "localname": "BroadyHealthSciencesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "nhtc_CommonStockSpecialDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special dividends declared during the period for each share of common stock outstanding.", "label": "CommonStockSpecialDividendsPerShareDeclared", "terseLabel": "CommonStockSpecialDividendsPerShareDeclared" } } }, "localname": "CommonStockSpecialDividendsPerShareDeclared", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "perShareItemType" }, "nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents cumulative translation adjustment realized in net income.", "label": "Cumulative Translation Adjustment Realized In Net Income", "negatedTerseLabel": "Cumulative Translation Adjustment Realized In Net Income" } } }, "localname": "CumulativeTranslationAdjustmentRealizedInNetIncome", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Document And Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "xbrltype": "stringItemType" }, "nhtc_EnrollmentPackageRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents enrollment package revenue.", "label": "Enrollment Package Revenue [Member]", "terseLabel": "Enrollment Package Revenue [Member]" } } }, "localname": "EnrollmentPackageRevenueMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_EquityIncentive2016PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive 2016 Plan", "label": "Equity Incentive 2016 Plan [Member]", "terseLabel": "Equity Incentive Plan 2016" } } }, "localname": "EquityIncentive2016PlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "nhtc_FinancialInstitutionInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to financial institution instruments.", "label": "Financial Institution Instruments [Member]", "terseLabel": "Financial Institution Instruments [Member]" } } }, "localname": "FinancialInstitutionInstrumentsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "nhtc_GILTIprovisionaltaxnetofforeigncredits": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "GILTI provisional tax, net of foreign credits", "label": "GILTI provisional tax, net of foreign credits", "terseLabel": "GILTI provisional tax, net of foreign credits" } } }, "localname": "GILTIprovisionaltaxnetofforeigncredits", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_INCOMETAXESAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "INCOME TAXES [Abstract]", "label": "INCOME TAXES [Abstract]" } } }, "localname": "INCOMETAXESAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "xbrltype": "stringItemType" }, "nhtc_MunicipalBondsAndNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds and Notes [Member]", "terseLabel": "Municipal Bonds and Notes [Member]" } } }, "localname": "MunicipalBondsAndNotesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of days termination notice.", "label": "Number Of Days Termination Notice", "terseLabel": "Number of days for termination notice" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "durationItemType" }, "nhtc_ReStoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a product called ReStore\u2122.", "label": "ReStore [Member]", "terseLabel": "ReStore" } } }, "localname": "ReStoreMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "nhtc_RevenuePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "revenue percentage by geographic location", "label": "Revenue Percentage", "terseLabel": "Revenue Percentage" } } }, "localname": "RevenuePercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "percentItemType" }, "nhtc_RevenueTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue [Text Block]", "label": "Revenue [Text Block]", "terseLabel": "Revenue [Text Block]" } } }, "localname": "RevenueTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueNotes" ], "xbrltype": "textBlockItemType" }, "nhtc_RoyaltyRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the royalty rate.", "label": "Royalty Rate", "terseLabel": "Royalty rate" } } }, "localname": "RoyaltyRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "percentItemType" }, "nhtc_RussiaandKazakhstanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Russia and Kazakhstan [Domain]", "label": "Russia and Kazakhstan [Domain]", "terseLabel": "Russia and Kazakhstan [Domain]" } } }, "localname": "RussiaandKazakhstanDomain", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "nhtc_SalesReturnRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales Return Rate - percentage of sales refunded/returned", "label": "Sales Return Rate", "terseLabel": "Sales Return Rate" } } }, "localname": "SalesReturnRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "percentItemType" }, "nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Balance Sheet Components [Table Text Block]", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]", "terseLabel": "Schedule of Additional Balance Sheet Components [Table Text Block]" } } }, "localname": "ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "nhtc_SecuritiesClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Securities Class Action [Member]", "label": "Securities Class Action [Member]", "terseLabel": "Securities Class Action" } } }, "localname": "SecuritiesClassActionMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_ShareholderderivativeclaimMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "shareholder derivative claim [Member]", "label": "shareholder derivative claim [Member]", "terseLabel": "shareholder derivative claim [Member]" } } }, "localname": "ShareholderderivativeclaimMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents unshipped product.", "label": "Unshipped Product [Member]", "terseLabel": "Unshipped Product [Member]" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20180331", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r9", "r31", "r33", "r52" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued Employee Benefits, Current" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r38", "r240", "r251" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r39", "r240", "r251" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued Income Taxes, Noncurrent" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r66", "r70", "r207" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r68", "r69", "r70" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Balance, March 31, 2018", "periodStartLabel": "Balance, December 31, 2017", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r67", "r70", "r207" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r63", "r70", "r207" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r42" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r180", "r189", "r191" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continents of North and South America.", "label": "Americas [Member]", "terseLabel": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r1", "r8", "r10", "r116" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r239", "r250" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r28", "r29", "r61" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r129", "r130", "r133" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Available-for-sale Securities, Amortized Cost Basis" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r131", "r132", "r134", "r135", "r138", "r247", "r248" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Available-for-sale Securities [Table Text Block]" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r181", "r190" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r3", "r47" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r4", "r26", "r47", "r92" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r86", "r222" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r3", "r4", "r35", "r93", "r98", "r126" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r4", "r35" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r3", "r35" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r148", "r242", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r54", "r147", "r151", "r157", "r221" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Common (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r41" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at March 31, 2018 and December 31, 2017" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r7", "r17", "r18", "r73" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CondensedBalanceSheetStatementTable": { "auth_ref": [ "r24", "r104", "r202", "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet Statement [Table]", "terseLabel": "Condensed Balance Sheet Statement [Table]" } } }, "localname": "CondensedBalanceSheetStatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]" } } }, "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r98", "r205", "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent", "verboseLabel": "Long-term incentive" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r175", "r176" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r32", "r171", "r172", "r173", "r174", "r175", "r176" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r32", "r170" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r32", "r170", "r171", "r172", "r173", "r174", "r175" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Deferred Revenue, Revenue Recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent": { "auth_ref": [ "r194", "r195", "r199" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, netted by jurisdiction and classified as current.", "label": "Deferred Tax Assets, Net, Current", "terseLabel": "Deferred Tax Assets, Net, Current" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r194", "r195", "r196" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r90", "r145" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dividends [Abstract]", "terseLabel": "Cash dividends declared per share:" } } }, "localname": "DividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r112", "r117", "r119", "r245", "r257" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r112", "r245", "r257" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r98", "r116", "r117", "r118" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r80", "r112", "r114", "r115", "r119" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r222" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r212", "r216", "r217", "r218", "r219", "r220" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r98", "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r142", "r143", "r144" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r74", "r238", "r243", "r258" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r13", "r103", "r200" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r98", "r192", "r193", "r197", "r198", "r201", "r262" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).", "label": "Increase (Decrease) in Customer Advances and Deposits", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCustomerAdvancesAndDeposits", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r113", "r117" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r57" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory, Finished Goods, Gross" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r27", "r59", "r140" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventory, Net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r58" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Inventory, Raw Materials and Supplies, Gross" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r59", "r105", "r140", "r141" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedTerseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r213", "r259", "r260", "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r213", "r259", "r260", "r261" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r50" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r46", "r241", "r253" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of judgment or settlement awarded to (against) the entity in respect of litigation.", "label": "Litigation Settlement, Amount", "terseLabel": "Litigation Settlement, Amount" } } }, "localname": "LitigationSettlementAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r86", "r88" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r86", "r88" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r86", "r87", "r91" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r17", "r18", "r75", "r91", "r117", "r244", "r256" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r110", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r0", "r5", "r11", "r14", "r22", "r106", "r107", "r108", "r120", "r121", "r122" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements", "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r31", "r33", "r34", "r52" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Accrued Liabilities, Current", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r60" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r64", "r68", "r223", "r224", "r227", "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r62", "r225" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r68", "r71", "r72", "r226" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r203", "r204", "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r65", "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized losses on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCreditsCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unearned revenue or income classified as other, expected to be taken into income within one year or the normal operating cycle, if longer.", "label": "Other Deferred Credits, Current", "verboseLabel": "Amounts held in eWallets" } } }, "localname": "OtherDeferredCreditsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r30", "r31", "r52" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r12", "r85" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r15", "r84" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r181", "r190" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r40" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductOrServiceAxis": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Information by products and services or groups of similar products and services.", "label": "Products and Services [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ProductsAndServicesDomain": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products and Services [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r36", "r37", "r146", "r254" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r16", "r20", "r21", "r229", "r230", "r231" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r102", "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r43", "r164", "r252" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r97", "r98", "r99", "r177" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition, Policy [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueRecognitionPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "terseLabel": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesReturnsGoods": { "auth_ref": [ "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails": { "order": 3.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate refunds recognized during an accounting period due to goods returned by customers (other than under warranty provisions). Returns are a deduction from gross revenue in arriving at net revenue.", "label": "Sales Returns, Goods", "negatedTerseLabel": "Sales Returns, Goods" } } }, "localname": "SalesReturnsGoods", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsGross": { "auth_ref": [ "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails": { "order": 1.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Gross", "terseLabel": "Sales Revenue, Goods, Gross" } } }, "localname": "SalesRevenueGoodsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNet": { "auth_ref": [ "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Net", "terseLabel": "Net sales", "totalLabel": "Sales Revenue, Goods, Net" } } }, "localname": "SalesRevenueGoodsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r2", "r131", "r132", "r134", "r135", "r136", "r137", "r247", "r248" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Revenue from External Customers by Products and Services [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r102", "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r181", "r190" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentGeographicalDomain": { "auth_ref": [ "r25", "r125", "r263" ], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r82", "r139" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, ending balance (in shares)", "periodStartLabel": "Nonvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "periodStartLabel": "Nonvested, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r179", "r184" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShippingAndHandlingRevenue": { "auth_ref": [ "r77", "r178" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails": { "order": 2.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fees charged to customers for the delivery, generally by postal or freight service providers, of product or goods purchased.", "label": "Shipping and Handling Revenue", "terseLabel": "Shipping and Handling Revenue" } } }, "localname": "ShippingAndHandlingRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r56", "r159" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementGeographicalAxis": { "auth_ref": [ "r25", "r125", "r263" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of treasury stock for employee awards, net" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r40", "r41", "r159", "r164" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Gross" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, amount authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r41", "r44", "r45", "r127" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r19", "r41", "r44", "r45", "r100", "r101", "r128", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r167" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r55", "r166" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r55", "r166", "r168" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 1,603,322 and 1,637,524 shares at March 31, 2018 and December 31, 2017, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r115" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r23", "r109", "r115" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Glossary": "Accounting Change", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6503790" }, "r1": { "Glossary": "Antidilution", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505113" }, "r10": { "Glossary": "Diluted Earnings Per Share", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510752" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256" }, "r11": { "Glossary": "Direct Effects of a Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=66092750" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258" }, "r12": { "Glossary": "Financing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6513228" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558" }, "r13": { "Glossary": "Income Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515339" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27340-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r14": { "Glossary": "Indirect Effects of a Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515603" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349" }, "r15": { "Glossary": "Investing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6516133" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644" }, "r16": { "Glossary": "Management", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6517382" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1 Response))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r17": { "Glossary": "Net Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831255" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.B.Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=68075638&loc=d3e60635-111653" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r18": { "Glossary": "Other Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831270" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r19": { "Glossary": "Preferred Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521494" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r2": { "Glossary": "Available-for-Sale Securities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505594" }, "r20": { "Glossary": "Principal Owners", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521851" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=d3e5283-111683" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569643-111683" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r21": { "Glossary": "Related Parties", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=16382449" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612" }, "r22": { "Glossary": "Retrospective Application", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6523989" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32157-110900" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r229": { "Glossary": "Affiliate", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6504562" }, "r23": { "Glossary": "Weighted-Average Number of Common Shares Outstanding", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528421" }, "r230": { "Glossary": "Control", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6508935" }, "r231": { "Glossary": "Immediate Family", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6515043" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04(c)(Schedule I))", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-06)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.7-05(c)(Schedule II))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04.(c) Schedule III)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r264": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765" }, "r3": { "Glossary": "Cash", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506951" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Glossary": "Cash Equivalents", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507016" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Glossary": "Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507316" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Glossary": "Common Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508022" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e),(f),(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580" }, "r7": { "Glossary": "Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831223" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r8": { "Glossary": "Contingent Stock Agreement", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508534" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.21)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r9": { "Glossary": "Current Liabilities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509677" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18823-107790" } }, "version": "2.0" } ZIP 57 0000912061-18-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000912061-18-000022-xbrl.zip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